PNPLA2 and obesity due to melanocortin 4 receptor deficiency: Furthermore, recent publications provide proof of concept that chemical inhibition of ATGL might be a good therapeutic strategy for treating obesity and related metabolic diseases as mice treated with atglistatin showed reduced adipose tissue lipolysis, weight gain, and insulin resistance (60, 65, 66, 67).